ERBB2 and cancer: In summary, we reported a novel fully human monoclonal antibody against HER2, GB235, which bound to domain III of HER2 ECD and displayed potential efficacy inhibiting HER3-mediated signaling in heregulin-induced Trastuzumab resistant cancer cells.